Context: Glycogen storage disease (GSD) type XV is a rare disease caused by mutations in the GYG1 gene that codes for the core molecule of muscle glycogen, glycogenin 1. Nonetheless, glycogen is present in muscles of glycogenin 1-deficient patients, suggesting an alternative for glycogen buildup. A likely candidate is glycogenin 2, an isoform expressed in the liver and heart but not in healthy skeletal muscle.
G lycogen storage diseases (GSDs) encompass a group of diseases in which the formation or metabolism of glycogen is perturbed. GSD type XV is caused by mutations in the GYG1 gene, which codes for glycogenin 1, the protein that forms the core of glycogen in skeletal and cardiac muscle. To date, only 22 patients with GSD type XV have been reported worldwide (1) (2) (3) (4) (5) (6) (7) (8) (9) . Patients generally have a late onset of the disease from 20 to 50 years of age, with progressive, widespread muscle weakness and wasting. Cardiac involvement has been reported in only four patients and, curiously, these patients did not show skeletal muscle affection (1, 9) . Conversely, patients with skeletal muscle affection did not have cardiac disease (2) (3) (4) (5) (6) (7) (8) . Creatine kinase is usually normal or mildly elevated, and histology generally does not demonstrate degeneration, suggesting that the disorder has little impact on the structure and function of muscle fibers (6) . Polyglucosan (PG) bodies, consisting of glycogen/ polysaccharides, are a histopathological hallmark of this disease and stain intensely with periodic acid-Schiff (PAS) (1) . PG bodies have been shown to contain polysaccharides that are partly resistant to amylase degradation (2, 6) . For proper initiation of glycogen synthesis, glycogenin 1 forms dimers (10) . Glycogenin 1 possesses autocatalytic properties, with the catalytic site around Asp159 and Asp162, using uridine diphosphate-glucose to add the first few glucose moieties on Tyr194 of the protein (11) (12) (13) . This serves as a priming sequence for glycogen synthase and, later, glycogen branching enzyme 1 (GBE1). In absence of glycogenin 1, proper formation of glycogen in muscle should not be possible; yet, glycogen has been detected in patients with GSD type XV (1) (2) (3) (4) (5) (6) (7) (8) (9) . This glycogen appears to have normal granule structure, which implies a core molecule possessing the ability to autoglycosylate, as this is required for elongation by glycogen synthase. So far, only one other core molecule is known, glycogenin 2, an isoform of glycogenin 1 that is found in liver, heart, and kidney but not in skeletal muscle of healthy individuals (14) . In this study, we report two new patients with pathogenic mutations in GYG1, which led to total loss of glycogenin 1. We demonstrate how the glycogenin 1 deficiency affects general morphology, the ultrastructure of the muscle, and glucose metabolism, but also that glycogenin 1 deficiency does not preclude formation of glycogen in muscle. Both patients expressed significant amounts of glycogenin 2 in skeletal muscle. This finding likely explains the presence of normal-appearing glycogen in the patients, regardless of the absence of glycogenin 1.
Methods

Participants
Two ambulatory female patients with mutations in GYG1 were included in this study. Patient 1, age 77 years, carrying c.166G.C (p.Asp56His)/c.472Del (p.Asp160Thr fs*5) mutations in GYG1, had disease onset at ;50 years old. Patient 2, age 46 years, is homozygous for c.487del (p.Asp163Thrfs*5) mutation in GYG1 and had disease onset at around age 30. Glycogen content was assessed in comparison with genetically verified patients with Pompe disease (GSD type II), glycogen debrancher deficiency (GSD type III), McArdle disease (GSD type V), and phosphorylase kinase deficiency (GSD type IX) and healthy, sedentary female controls (age 39 6 10 years).
The two patients have previously been studied during a 1-hour cycle exercise test during which euglycemia was maintained, and the insulin response to exercise was normal (15) . That study indicated that muscle glycogen breakdown is partially impaired in glycogenin 1-deficient patients and that the sympathoadrenal response is exaggerated in exercise, so that delivery of glucose from the liver is enhanced, which partially compensates for the impaired muscle glycogenolysis.
Histology
Vastus lateralis muscle biopsies were sectioned on a cryostat and stained for hematoxylin and eosin for general histopathological evaluation. PAS stain was used to stain for glycogen using the manufacturer's protocol (Sigma-Aldrich, St. Louis, MO). To test for amylase-resistant glycogen, sections were incubated in 10 mg/mL human saliva a-amylase (Sigma-Aldrich) at 37°C for 1 hour and PAS stained. Gomori-modified trichrome and succinyl dehydrogenase (SDH) stains were used to detect mitochondria. Myosin heavy chain (MHC) slow stain (MHC type I) was used for fiber typing (Vector Laboratories, Burlingame, CA).
Visualization of PG bodies by electron microscopy
To visualize the ultrastructure in the myofibrils of muscle from patients with GSD type XV, we performed electron microscopy on a sample from patient 2 using a protocol previously described (16) . Briefly, a piece of fresh muscle biopsy was perfused with 2% electron microscopy-grade glutaraldehyde in 0.05 M phosphate buffer. After postfixation and staining, the biopsy was embedded in epon and sectioned both at a transverse and longitudinal orientation. Sections were visualized in a CM100 transmission electron microscope (EM) (Philips, Amsterdam, Netherlands) fitted with a 4-megapixel Veleta camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany). EM images were acquired with a specific focus on fibers with PG bodies. Measurement of glycogen granules was performed on 100 granules using a calibrated scale embedded in the EM micrographs and Adobe Photoshop CS5 (Adobe, San Jose, CA).
Immunohistology
For visualization of fibrillar proteins in PG bodies, vastus lateralis muscle was sectioned on a cryostat, blocked with fetal bovine serum, and stained with antibodies against MHC I at 1:40 [clone BA-D5; Developmental Studies Hybridoma Bank (DSHB), University of Iowa, Iowa City, IA], MHC IIA at 1:100 (clone SC-71; DSHB), muscle actin at 1:50 (clone HHF-35, VP-M659; Vector Laboratories), desmin at 1:100 (ab32362; Abcam, Cambridge, United Kingdom), a-tubulin at 1:50 (clone 12G10; DSHB), aB-crystallin at 1:100 (ab13496; Abcam), and filamin C (HPA006135; Sigma-Aldrich). Sections were stained with Alexa Fluor 594 fluorescent goat anti-mouse and goat antirabbit secondary antibodies at 1:500 (Thermo Fisher, Waltham, MA) and mounted with Fluorosave (Merck Millipore, Temecula, CA). Stained sections were investigated using a Nikon Ti-E inverted microscope with a plan apo 320 air and 360 water immersion objective (Nikon Instruments Europe, Amsterdam, Netherlands) and visualized with an Andor Neo camera (Andor, Belfast, Northern Ireland).
Glycogen determination
Determination of glycogen in muscle tissue, sectioned on a cryostat, was performed according to the manufacturer's protocol (ab169558; Abcam). Briefly, glycogen is hydrolyzed into glucose by glucoamylase, which is oxidized by glucose oxidase to form an intermediate that reduces a colorless probe to a colored product with strong absorbance at 450 nm. Colorimetric reaction was measured on a Multiskan Go plate reader (Thermo Scientific, Vantaa, Finland), and results were analyzed on SkanIt 3.2 software (Thermo Scientific).
Western blotting
The western blotting protocol has previously been described in detail (16) . Briefly, vastus lateralis muscle biopsies from the patients and a healthy sedentary woman, age 42, were sectioned on a cryostat, homogenized in ice-cold lysis buffer with protease and phosphatase inhibitors, and centrifuged. The supernatants were separated on gels and blotted to polyvinylidene difluoride membranes, which were incubated in primary antibody. and malin (NHLRC1, ab186261, Abcam) were used. As loading control, anti-glyceraldehyde 3-phosphate dehydrogenase was used at 1:5000 (ab22555, Abcam). Secondary goat anti-rabbit antibodies coupled with horseradish peroxidase, diluted 1:10,000, were used to detect primary antibodies (DAKO, Glostrup, Denmark). Immunoreactive bands were detected using SuperSignal West Dura (Thermo Fisher) and visualized using a GBox XT16 darkroom (Syngene, Cambridge, United Kingdom).
Determination of glycogenin 1 and 2 protein levels
To determine the level of glycogenin 1, two muscle tissue lysates were made for each patient; one was treated with 10 mg/ mL a-amylase for 1 hour at 37°C, to release all glucose from the core glycogenin 1 dimer, whereas the other was untreated. Both lysates were then mixed with the sample buffer and run on a gel and blotted as stated earlier. The blot was incubated with antibodies against glycogenin 1 at 1:1000 (ab111711, Abcam) or glycogenin 2 at 1:500 (ab209784, Abcam) overnight at 4°C and with secondary goat anti-rabbit horseradish peroxidaseconjugated antibody for 3 hours at room temperature and visualized as described previously.
Ethical statement
All participants had provided written consent for participation in the study. The Ethical Committee for the Capital Region had approved the study (H-15015150).
Results
Histology
In patient 1, muscle sections stained with hematoxylin and eosin for general histology evaluation showed increased variability of fiber size, moderate cellular infiltration, and newly formed regenerating myofibers in focal areas, suggesting a mild to moderate myopathy [ Fig. 1(a) ]. In PAS stain for glycogen, PG bodies typically stained in the periphery of the fiber, whereas the remaining part of the fiber was completely devoid of glycogen [ Fig. 1(b) ]. Patient 2 showed normal fiber size and shape with few PG bodies containing fibers. None of the PG fibers were resistant to a-amylase treatment, hence the glycans in the PG fibers did not contain excessive branching, which would have rendered digestion of the glycans to glucose difficult [ Fig. 1(c-e) ]. Fibers containing PG bodies were often grouped as four to six fibers. Trichrome stain is useful for visualizing, among other things, excessive levels of especially subsarcolemmal mitochondria, giving the fiber a ragged appearance throughout the entire fiber as the excessive level of mitochondria stain dark red. SDH is also a stain for general mitochondrial activity, and excessive levels of mitochondria would yield a ragged blue fiber. However, trichrome and SDH stains did not reveal ragged red/blue fibers, suggesting that excessive mitochondrial proliferation was not an issue in the patients [ Fig. 1 (f) and 1(g)]. To assess for possible mitochondrial dysfunction, we stained for cytochrome oxidase, which is a marker for mitochondrial activity as cytochrome oxidase is part of complex IV, and found that this staining appeared normal. PG bodies were restricted to MHC type 1 (slow oxidative) fibers [ Fig. 1(h) ]. The number of fibers with PG bodies was 2.7% in patient 1 (35 PG of 1318 total fibers) and 0.5% in patient 2 (7 PG of 1551 total fibers).
Ultrastructure by electron microscopy
Electron microscopy of the glycogenin 1-deficient biopsies clearly demonstrated glycogen granules located within the myofibrils in close proximity to mitochondria in type I oxidative fibers [ Fig. 2 However, sarcomeric proteins like MHC type I and actin, which were abundantly present in myofibrils, were not found in the inclusions [ Fig. 4 (i) and 4(j)]. Glycogen granule diameter was 35 6 4 nm (N = 100; range, 26 to 45 nm).
Glycogen determination
We determined the glycogen concentration in muscle biopsies from glycogenin 1-deficient patients, healthy controls, and patients with other muscle glycogenoses (GSD types II, III, V, and IX) and found that the glycogen content in the glycogenin 1-deficient patients was near normal. In the four other muscle glycogenoses, glycogen levels were 2 to 15 times higher (Table 1) .
Glycogenin and glycogen metabolism
Glycogenin 1 was not detected in any of the non-aamylase-treated samples. However, in the a-amylasetreated samples, glycogenin 1 monomer was still not detectable in glycogenin 1-deficient patients, whereas it was clearly present in healthy controls [ Fig. 5(a) ]. Interestingly, the a-amylase treatment led to a multitude of bands in the glycogenin 1-deficient patients and controls. Glycogenin 2 was detected in the patients, much stronger in the more affected patient 2 than in patient 1, but not in any of the controls [ Fig. 5(b) ]. Because absence of glycogenin 1 should interfere with normal glycogen formation, it likely could have secondary downstream effects on muscle glucose metabolism. We investigated the activation and expression level of key enzymes involved in glucose metabolism and glycogen synthesis and breakdown [ Fig.  5(c) ]. Notably, we found that pAkt activation was increased in both glycogenin 1-deficient patients, suggesting involvement of insulin-mediated glucose uptake rather than glucose uptake through muscle contraction-induced AMPK activation, which was not different from the control in either patient. Consistent with this, we did not see any change in the level of the glucose transporter GLUT4 [ Fig.  5(c) ]. Phosphorylation of CaMKII, a kinase activated by a contraction-induced increase in Ca 2+ concentration and an inhibitor of glycogen synthase, was modestly increased. Activation of GSK3 (pGSK3) was also modestly increased, inhibiting its ability to inactivate glycogen synthase. Further downstream of the glycogen synthesis, an increase in glycogen synthase, but also an increase in phosphorylation of the synthase and inhibition of the enzyme, was evident, possibly caused by CaMKII. Glycogen branching enzyme was downregulated. In the breakdown pathway, no change in phosphorylation was seen in protein kinase A (PKA), which is activated by an increase in the level of epinephrine, but glycogen phosphorylase and glycogen debranching enzyme were both upregulated. Hexokinase II protein, involved in direct metabolism of blood glucose, was decreased in both patients compared with the control.
However, we found no change in the level of phosphoglucomutase, the enzyme responsible for converting hexokinase II phosphorylated glucose 6-phosphate to glucose 1-phosphate, an intermediate molecule that is subsequently converted to uridine diphosphate-glucose for incorporation in glycogen. Neither did we see any change in phosphofructokinase, which converts glucose 6-phosphate derived from hepatic glucose or glycogen to fructose 6-phosphate for further processing down the glycolysis pathway. Two important proteins involved in the branching of glycogen, laforin and malin, were not expressed differently from controls [ Fig. 5(d)] .
Discussion
This study has demonstrated the following: (1) Glycogenin 1 deficiency does not preclude synthesis of nearnormal levels of glycogen. Glycogenin 2, which is normally The glycogenin 1 deficiency led to an apparent decrease of hexokinase II protein, potentially causing attenuated blood glucose processing. Collectively, the findings could point to an energy deficiency that does not originate from loss of glycogen but rather from an inaccessibility of intrafibrillar glycogen, due to mislocalization and pooling of glycogen to the interfibrillar space. The presence, effect, and localization of glycogen Despite the total absence of glycogenin 1, glycogen granules were observed at the EM level in the patients, results that are consistent with previous findings (2, 5, 8, 9) . This finding also serves to validate the biochemical determination of glycogen in this study, which otherwise could be argued to be due to other carbohydrate structures. We have demonstrated that the level of glycogen, particularly in type II fibers, disrupts the ultrastructure and causes Z-line fragmentation, which has been demonstrated in one patient previously (5) . How glycogen is formed despite absence of glycogenin 1 has not been studied before. Our findings that the glycogen granules in glycogenin 1-deficient muscle resemble normal granules in shape and electron density point to an alternative mechanism by which glycogen is formed. The granules in healthy individuals are within the size range of 10 to 44 nm in diameter, with an average of 25 nm. The upper limit of glycogen granule size is determined by optimal availability of glucose molecules for enzymatic degradation, and the range in size reflects an ongoing demand for glucose as fuel rather than de novo synthesis of glycogen (17) . However, in the current study, glycogen granules in glycogenin 1-deficient muscle were invariably at the high end of this range with an average diameter of 35 nm (26 to 45 nm). This size corresponds to the size of human b-particles of liver glycogen (average 38 nm in fasting humans), which also is based on glycogenin 2 (18) . It can be speculated that the 50% larger size of glycogenin 2 compared with glycogenin 1 in terms of molecular weight also leads to larger glycogen granules compared with that found in normal muscle, provided that the number of glucose chain layers around glycogenin remains the same, limited by terminal layer density of glucose molecules (19, 20) . The glycogen molecules in muscle did not form higher-order structures like a-particles found in liver glycogen, possibly because proteins needed for the assembly of these structures are not expressed in muscle. This larger size may have an impact on glucose release as the glycogen is found mostly between, instead of within, myofibrils, potentially leading to a state of energy deficiency when energy is needed (i.e., during exercise). In accordance with this, preliminary results indicate that carbohydrate oxidation is impaired in GSD type XV during exercise (15) . In both patients, glycogen synthase 1 is upregulated and glycogen branching enzyme is downregulated. This change from normal could alter the level of branching to a lesser branched glycogen and thus a less energy-dense glycogen granule (21).
Glycogenin 2 compensation
A key finding was the presence of glycogenin 2 in both biopsies of the glycogenin 1-deficient patients but not in healthy controls. Glycogenin 2 resembles glycogenin 1, with a catalytic site and a tyrosine initiation site for extending the carbohydrate chain. However, it is ;50% bigger than glycogenin 1 and abundantly present in liver and heart, but not in healthy skeletal muscle (14, 22) . The presence of glycogen granules despite the absence of glycogenin 1 suggests that glycogenin 2 is the compensating core molecule in the glycogen granules found in the patients. It is interesting that this restriction of glycogenin 2 expression in skeletal muscle can be lifted, but the coexistence of glycogenin 1 and 2 in liver and heart suggests that coexpression can occur in the same tissue. In this context, it is noteworthy that glycogenin 1 and 2 are capable of heterodimerization and that glycogen synthase 1 can add terminal glucosyl units to both (23) . It is possible that glycogen synthase 2, which is liver specific, and other proteins involved in glycogen synthesis and breakdown are expressed in a compensatory way in patients with glycogenin 1 deficiency. However, expression of glycogen synthase 2 has, to our knowledge, not been demonstrated in skeletal muscle, consistent with the severe phenotype of glycogen synthase 1 deficiency (GSD 0, muscle variant), in which patients do not present any glycogen (24) . Hence, in this study, we have not investigated this issue. Our results demonstrate that glycogenin 2 was found in patient samples not treated with a-amylase, suggesting a significant de novo expression unlike the de novo expression of glycogenin 1, which is very low, due to the extension or breakdown of glucosyl branches during glycogen metabolism rather than complete breakdown of the entire molecule (25) . However, we are puzzled by the consistently lower level of glycogenin 2 found in the a-amylase-treated samples compared with the nontreated samples. We speculate that this could be due to proteolytic breakdown if the protective effect of the glucosyl chains is not present.
PG bodies with glycogen granules and filament proteins
A hallmark of glycogenin 1 deficiency is the presence of PG fibers, containing inclusions of various sizes and shapes within a myofiber. It is interesting that our study demonstrates that PG fibers are exclusively found in type I oxidative fibers. This is consistent with earlier findings in the myocardium, which is constituted to a great extent by oxidative type I fibers (1). We did not observe a-amylase-resistant glycogen or carbohydrate structure, especially in PG fibers in PAS stains of the muscle from the Figure 5 . Glycogenin 2 compensation for absent glycogenin 1 and changes in glycogen metabolism. (a) Western blot of muscle with (+) and without a-amylase (-) treatment of the lysate prior to separation on a polyacrylamide gel demonstrates that neither of the patients has glycogenin 1 (black arrowheads), which is visible only when deglycosylated by a-amylase, as in the treated control. The amylase-treated samples do however demonstrate the release of some glycogen priming molecule found in both patients and the control, but at a significantly higher level in patients. (b) Western blot of the liver isoform glycogenin 2 demonstrates upregulated protein in the patients but none at all in the control. (c) Key signaling proteins and enzymes involved in glycogen synthesis and breakdown as well as glucose metabolism (in green) were analyzed in the glycogenin 1-deficient patients and control. In direct relation to the glycogenin 1 deficiency, an increase in phospho-glycogen synthase (pGS) and decrease in glycogen branching enzyme in both patients demonstrate that glycogen synthesis by elongation and branching of polysaccharides is decreased compared with the control. Downregulation of hexokinase II (HKII) and phospho-fructo kinase (PFK) upregulation, perhaps as compensation, suggest that direct metabolism of blood glucose appears downregulated. (d) Laforin and malin are involved in glycogen branching and exist in a steady-state relationship. No change in expression is seen between patients and control. AMPK, 5 0 AMPactivated protein kinase; CaMKII, Ca 2+ /calmodulin-dependent protein kinase II; Ctrl, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GDE, glycogen debranching enzyme; GLUT4, glucose transporter 4; GN1/2, glycogenin 1/2; GP, glycogen phosphorylase, muscle isoform; GSK3, glycogen synthase kinase 3; PGM, phosphoglucomutase; PHKA1, phosphorylase kinase a1; Pt.1, patient 1; Pt.2, patient 2; UDP, uridine diphosphate. glycogenin 1-deficient patients. Previous reports were not consistent with this finding, as partly a-amylaseresistant PG bodies were suggested to contain polysaccharides with a different molecular structure (8) . Long unbranched or low-level branched carbohydrates are seen in Lafora disease, produced by mutations in laforin (EPM2A/NHLRC1) or malin (EPM2B), the ubiquitin ligase that removes laforin, causing a loss in control of branching points (26) . However, we demonstrated that laforin and malin are expressed at normal levels in the glycogenin 1-deficient patients. This argues against unbranched carbohydrates. PG fibers are found in other diseases and form a group called PG body diseases, caused by mutations in the ubiquitin ligases RBCK1, malin, GBE1, laforin, phosphofructokinase (PFKM), PRDM8, and PRKAG2 (27) . This study clearly demonstrates that the inclusions contain glycogen granules, organelles, mostly mitochondria, and filament proteins, such as desmin and filamin C, and likely other filament proteins as well. Sarcomeric proteins were not found in the inclusions, probably due to the fact that they are processed swiftly for degradation through a distinct ubiquitination process involving the E3 ubiquitin ligase MuRF1, which was found to be upregulated in three related patients in a previous study (5) . This ubiquitin ligase is also involved in myostatin-dependent regulation of muscle mass as well as muscular atrophy (28) .
Dominant-negative effect of mutated glycogenin 1 in patients with cardiomyopathy
Of the ;20 patients reported so far with glycogenin 1 deficiency, 4 were found to have cardiomyopathy, with a significant number of myofibers having large PG bodies in cardiac muscle (1, 9) . These patients all expressed autoglycosylation-deficient glycogenin 1. However, patients with complete absence of glycogenin 1, as the two patients reported in our study, have not been reported to suffer from cardiomyopathy. As cardiac muscle consists of type I fibers and, unlike skeletal muscle, expresses glycogenin 2, it is possible that the functional glycogenin 2 heterodimerizes with nonfunctional glycogenin 1, which then, by a dominant-negative effect, acts to render the dimer nonfunctional as shown in vitro (23) . This may create a local energy crisis leading to further downstream processes, which may involve breakdown of energy-consuming functional structures like sarcomeres, thus creating PG bodies, and explain the lack of sarcomeric proteins in these.
Localization and level of glycogen may create energy crisis and loss of structural integrity
Patients with glycogenin 1 deficiency evidently do not suffer from lack of glycogen, as shown by EM and demonstrated biochemically for the first time, to our knowledge, in the current study. However, three plausible factors may contribute to the disease. An energy deficit due to aggregation of glycogen molecules in dense interfibrillar pools may render them less available to energy-sensing enzymes like AMPK by sterically hindering the enzymes to attach to glycogen. Secondly, the energy requirement/feedback signal may be insufficient, leading to less blood glucose uptake or processing to cover immediate energy needs, which is supported by the decreased level of hexokinase II. Both of these factors could explain the impaired carbohydrate oxidation during exercise in these patients (15) . Based on the levels of the various enzymes we have investigated, a picture of energy crisis emerges as muscles attempt to increase glucose uptake through the insulin pathway, but hexokinase II may be a bottleneck both for glycogen synthesis and downstream glycolysis of hepatic glucose. However, as insulin normally leads to glycogen synthesis, rather than glycolysis, a compounding problem appears to emerge, possibly leading to an increase in the breakdown enzymes myophosphorylase and debranching enzyme as a response to the insufficient glucose flux. However, as myophosphorylase is activated by phosphorylase kinase (PHKA1), which in turn is activated by PKA, and no increase in phosphorylation is evident, the increased level of myophosphorylase may not have the intended effect. Although glycogen synthase is inhibited, but increased in expression, the net effect could be an activity level corresponding to a lower level of uninhibited/less inhibited glycogen synthase protein. In addition, inhibition of glycogen synthase could be caused by CaMKII, not GSK3 or PKA, downstream effectors of insulin and epinephrine acting on glycogen synthase. Third, the accumulated glycogen, particularly in type II fibers, may interfere with proper contractile function. PGM1 expression is near normal, suggesting that this shuttle providing glucose for as well as from glycogen is unaffected. It is however possible that hexokinase IV, the isozyme in liver, is upregulated in the same way as glycogenin 2 in muscle. This has not been investigated. This would further favor synthesis of glycogen, which the insulin-induced activation of Akt also suggests. The accumulation of glycogen in muscle evidently affects the myofibrillar structure in type II fibers, and occasionally in type I fibers when PG bodies are formed. The low incidence of PG fibers makes it unlikely that these contribute significantly to the myopathy experienced by the patients. In contrast, we have recently demonstrated in an animal model of McArdle disease (myophosphorylase deficiency), that a majority of myofibers are structurally affected by interfibrillar glycogen accumulation, which causes a disruption of myofibrillar structure (16) . This has also been seen in Pompe disease, where ruptured lysosomes cause glycogen to disrupt the myofibrillar structure at the Z-disc level (29) . The suggested pathogenetic causes of disease in GSD type XV may act in unison and explain both the exercise intolerance and the limb-girdle muscular dystrophy phenotype in patients with glycogenin 1 deficiency.
